Abstract | PURPOSE: METHODS: HER2-positive MBC patients received oral vinorelbine 40 mg thrice a week and trastuzumab (loading dose of 8 mg/kg, followed by 6 mg/kg every 3 weeks) until disease progression, unacceptable toxicity, or consent withdrawal. The primary endpoints were objective response rate (ORR), clinical benefit rate (CBR; CR + PR + SD for ≥ 24 weeks). The secondary endpoints were progression-free survival (PFS), tolerability, and overall survival (OS). RESULTS: Twenty patients with HER2-positive MBC were enrolled, with a median of 1 prior chemotherapy regimens for MBC. Median age was 61.5 years (95% Confidence Interval (CI) 48.6-63.1). Visceral involvements presented in 14 patients (70.0%). ORR was 20.0%, and CBR was 75% with 4 PR (20.0%) and 11 SD (55.0%). The median PFS (mPFS) and median OS (mOS) were 7.4 months (95% CI 3.2-11.5) and 45.8 months (95%CI: not reached), respectively. The mPFS was 17.7 months (95%CI not reached) and 5.8 months (95%CI 5.6-5.9) in mNH as first-line and ≥ second-line therapy (log rank p = 0.03), respectively. The most common grade 1 adverse events (AEs) included nausea (15%), leukopenia (15%), ALT/AST elevation (15%), diarrhea (10%), and peripheral neuropathy (10%). Grade 2 adverse events included leukopenia (5%) and neutropenia (10%). No grade 3/4 AEs were observed. CONCLUSIONS:
|
Authors | Zijing Wang, Jiaxuan Liu, Fei Ma, Jiayu Wang, Yang Luo, Ying Fan, Peng Yuan, Pin Zhang, Qing Li, Qiao Li, Binghe Xu |
Journal | Breast cancer research and treatment
(Breast Cancer Res Treat)
Vol. 188
Issue 2
Pg. 441-447
(Jul 2021)
ISSN: 1573-7217 [Electronic] Netherlands |
PMID | 33895900
(Publication Type: Clinical Trial, Phase II, Journal Article)
|
Chemical References |
- Receptor, ErbB-2
- Trastuzumab
- Vinorelbine
|
Topics |
- Antineoplastic Combined Chemotherapy Protocols
(adverse effects)
- Breast Neoplasms
(drug therapy, genetics)
- Female
- Humans
- Middle Aged
- Neoplasm Metastasis
- Prospective Studies
- Receptor, ErbB-2
(genetics)
- Trastuzumab
(adverse effects)
- Treatment Outcome
- Vinorelbine
(therapeutic use)
|